Abstract EZH2 is a Polycomb group protein that exerts oncogenic functions in breast cancer, where its overexpression is associated with metastatic disease. While it reportedly acts a transcriptional repressor through trimethylation of histone H3 at lysine 27, EZH2 may exhibit context-dependent activating functions. Despite associations with worse outcome and metastasis in breast cancer, a functional role of EZH2 in breast cancer metastasis in vivo has not been demonstrated. Furthermore, whether EZH2 regulates cancer cell phenotype and motility are unknown. In this study, we discovered that knockdown of EZH2 induces a phenotypic reprogramming from mesenchymal to epithelial, reduces motility, and blocks invasion in breast cancer cell lines. In vivo, EZH2 downregulation in MDA-MB-231 cells decreases spontaneous metastasis to the lungs. We uncover an unexpected role of EZH2 in inducing the p38 mitogen-activated protein kinase signaling pathway, an important regulator of breast cancer invasion and metastasis. In breast cancer cells, EZH2 binds to phosphorylated p38 (p-p38) in association with other core members of the Polycomb repressive complex 2, EED, and SUZ12, and EZH2 overexpression leads to increased levels of p-p38 and of activated, downstream pathway proteins. The effect on p-p38 was confirmed in vivo, where it correlated with decreased spontaneous metastasis. In clinical specimens of matched primary and invasive breast carcinomas, we found that EZH2 expression was upregulated in 100 % of the metastases, and that EZH2 and p-p38 were coexpressed in 63 % of cases, consistent with the functional results. Together our findings reveal a new mechanism by which EZH2 functions in breast cancer, and provide direct evidence that EZH2 inhibition reduces breast cancer metastasis in vivo.
Introduction
Breast cancer is the 2nd most common cause of cancerrelated deaths for women in the United States [1] . Despite advances in breast cancer detection and treatment strategies, metastatic breast cancer is essentially incurable and the 5-year-survival rate for women diagnosed with distant metastatic disease is only 23 % [2] . The degree of breast cancer cell differentiation directly impacts its metastatic ability; the more undifferentiated the primary invasive carcinoma, the greater likelihood to develop metastasis [3] . Thus, it is not surprising that dysregulation of cell type identity and differentiation programs directly impact breast cancer metastasis.
Polycomb group proteins are major regulators of cellular memory that function in multimeric complexes to regulate the expression of specific genes, mainly through transcriptional repression. Enhancer of zeste homolog 2 (EZH2) is the catalytic core member of the Polycomb repressive complex 2 (PRC2), which catalyzes the trimethylation of histone H3 lysine27 (H3K27me3) [4] [5] [6] . Although primarily functioning in gene repression, EZH2 has been shown to exhibit gene activating functions, at times through mechanisms independent of its histone methyltransferase activity [7] [8] [9] [10] . EZH2 is highly expressed in a wide range of human cancers and has been shown to mediate the expression of target genes involved in tumorigenesis, including cell cycle regulation and proliferation, stem cell maintenance, cell differentiation, and neoplastic cell transformation [11] [12] [13] . EZH2 protein is overexpressed in 55 % of invasive breast carcinomas, and is significantly associated with poorly differentiated, estrogen receptor negative (ER -) tumors [14] [15] [16] [17] . We have demonstrated that EZH2 is an independent prognostic biomarker in breast cancer as women with tumors expressing high EZH2 have worse disease free and overall survival than women with tumors expressing low EZH2 [14] . Despite these associations, direct demonstration that EZH2 downregulation decreases breast cancer metastasis is lacking.
The p38 mitogen-activated protein kinase (MAPK) signaling pathway plays a complex and key role in cancer progression by translating extracellular signals into cellular responses through phosphorylation of specific serine and threonine residues of downstream effector proteins, especially transcription factors and protein kinases. Four p38 isoforms have been identified, whose implications in tumorigenesis may depend on cell context and tumor type [19, 20] . Once activated, p38 has been associated with regulation of the epithelial-to-mesenchymal transition (EMT), invasion and motility of cancer cells, all cellular processes that are crucial to metastasis [19, 20] . Recently, elevated p38c expression was shown to be associated with a lower overall survival of patients with breast cancer [21] .
In this study, we demonstrate a previously undescribed function of EZH2: its role in cancer cell motility and cell phenotype. EZH2 knockdown in breast cancer cells induces a mesenchymal-to-epithelial transition (MET), decreases cancer cell motility and the speed of movement. We provide first evidence that EZH2 knockdown in breast cancer cells reduces lung metastasis in vivo. Mechanistically, EZH2 binds to phosphorylated p38 (p-p38) and upregulates p38 downstream signaling, while EZH2 inhibition in breast cancer cells decreases p-p38 binding, expression, and downstream signaling. The relevance of our in vivo and in vitro studies to human breast cancer is highlighted by the finding that human breast cancer distant metastases express high levels of EZH2 and p-p38. Taken together, this study identifies a novel function of EZH2 in controlling p-p38 activity, breast cancer cell motility, and metastasis.
Materials and methods

Cell culture
Breast cancer cell lines MDA-MB-231 and MCF7 and mammary epithelial cell line MCF10A were obtained from the American Type Culture Collection. All cell lines were grown under recommended conditions. The SUM149 breast cancer cell line was obtained from the S. Ethier Laboratory (Karmanos Cancer Institute) and cultured as previously reported [22] .
Enhancer of zeste homolog 2 knockdown using stable short-hairpin interfering RNA in lentivirus was completed as previously reported [17] . Cells were transduced and selected for antibiotic resistance with puromycin (SigmaAldrich, #P9620). EZH2 knockdown was also achieved using 3-Deazaneplanocin A (Cayman Chemical, #13828) at 1 lM for 5 days treating every other day. As previously reported, transient EZH2 overexpression was achieved through infection with an EZH2-encoding, myc-tagged pCMV for 48 h [18, 23, 24] . The p-p38 inhibitors, SB203580 (Cell Signaling, #5633) or SB202190 (Abcam, #120638) were used at 10 or 20 lM for 48 h.
Western blotting and immunoprecipitations
Cells were lysed in RIPA lysis buffer with protease and phosphatase inhibitors (Thermo Scientific, #89900, #78410 & #78420) and Western blot analyses were carried out using 50 lg of whole cell extract. Samples were separated by SDS-PAGE gels and transferred onto PVDF membranes; membranes were blocked and incubated with primary antibodies in 3 % BSA (Sigma-Aldrich, #A3059) in TBS-T (Bio-Rad, #161-0372, with 0.05 % Tween20) at 4°C overnight. Protein signals were visualized via chemiluminescence as described by manufacturer (Thermo Scientific, #32106). b-Actin-HRP (Santa Cruz, #47778) was used to confirm equal loading. Cell Signaling antibodies: rabbit monoclonals EZH2 (#5246), E-cadherin (#3195), SUZ12 (#3737), p38b (#2339), p38d (#2308), MAPKAPK-2 (#3042), Snail1 (#3879); rabbit polyclonals p38 (#9212), p38a (#9218), p38c (#2307), phospho-HSP27 (Ser82, #2401), phospho-MAPKAPK-2 (#3007); mouse monoclonals Snail1 (#3895) and HSP27 (#2402). Abcam antibodies: rabbit monoclonal Cytokeratin-18 (#32118), rabbit polyclonal EED (#4469), and mouse monoclonal trimethyl-Histone H3 (#6002). Additionally: rabbit polyclonal ACTIVE Ò -p38 MAPK (pTGpY, Promega, #V1211) and rabbit monoclonal Vimentin (Epitomics, #2707-1).
Immunoprecipitations (IPs) were conducted following protocol instructions (Sigma-Aldrich, #IP50 
Invasion and motility assays
In vitro invasion was performed using Matrigel Invasion Chambers (BD Biosciences, #354480) according to the manufacturer's instructions, in triplicate. Invasive cells on lower sides of chambers were crystal violet stained, airdried, and photographed. They were quantified using ImageJ to count colored pixels, or for colorimetric assays, inserts were treated with 10 % acetic acid to remove dye and absorbance was measured at 560 nm.
Random motion cell motility assays were carried out as previously described [21] . In brief, cells were plated on collagen-coated chambered coverslips at low density attaching overnight. Next day, cells were imaged every 10 min at 37°C for 24 h using the DeltaVision RT Live Cell Imaging System (Applied Precision, GE Healthcare) equipped with a UPlanAo 20X/0.7 NA lens at the University of Michigan Microscopy and Image analysis Laboratory. DIC images were acquired using SoftWoRx 3.5.1 software, and cell movements were quantified using MTrackJ/ImageJ software.
Spontaneous metastasis assay/human breast tissue and immunohistochemistry
Ten-week-old severe combined immunodeficiency mice (Jackson Laboratories) were used for examining tumorigenicity as previously reported [17] . Additional methods on the spontaneous metastasis assay, including information on tumor staining and staining quantifications, can be found in the Supplementary Methods.
A high-density tissue microarray containing 16 human primary invasive breast carcinomas with matched metastases was employed [25, 26] . Immunohistochemistry on formalin-fixed, paraffin-embedded tissue blocks was performed using anti-EZH2 (Cell Signaling, #5246, 1:150) and anti-phospho-p38 MAPK (Cell Signaling, #9216, 1:3,000). EZH2 and p-p38 expression were evaluated as low or high based on the intensity of staining and percentage of staining cells, following published literature [27] . The complete clinical and pathological information on these tumors is shown in Supplementary Table 1.
Results
EZH2 knockdown induces a mesenchymal-to-epithelial transition and decreases the ability of breast cancer cells to move
EZH2 overexpressing breast carcinomas have aggressive clinical behavior, high frequency of estrogen receptor negative status (ER -) and are associated with a high propensity to metastasize [14] . However, direct evidence that EZH2 regulates cancer cell phenotype and motility are lacking. To test the hypothesis that EZH2 knockdown may reduce the ability of breast cancer cells to move and invade into the surrounding tissues, we employed breast cancer cell lines MDA-MB-231 and SUM149, both of which are ER -, invasive, tumorigenic in vivo and express high levels of EZH2 protein in comparison to non-tumorigenic breast cell lines [17] . We utilized two independent and complementary methods to downregulate EZH2 protein levels in breast cancer cells: stable expression of a short-hairpin RNA interference (shRNA) in a lentiviral vector and pharmacologic inhibition using 3-Deazaneplanocin A (DZNeP), a histone methyltransferase inhibitor which disrupts PRC2 (Fig. 1a, Supplementary Fig. 1a ).
EZH2 knockdown through either shRNA or DZNeP treatment was sufficient to induce a morphologic and a molecular MET of SUM149 and MDA-MB-231 cells when compared to scrambled shRNA or untreated controls, respectively (Fig. 1a, b, Supplementary Fig. 1a, b) . The observed morphological change was associated with a protein expression profile characteristic of MET: increased expression of the epithelial markers Cytokeratin-18 and E-cadherin and decreased expression of the mesenchymal markers Vimentin and Snail1 (Fig. 1a, Supplementary  Fig. 1a) . Knockdown of EZH2 with shRNA or DZNeP significantly reduced invasion in MDA-MB-231 and SUM149 cells when compared to corresponding controls (Fig. 1c, Supplementary Fig. 1c) .
We next investigated the role of EZH2 on cell motility, a critical step in metastasis. Random cell motion was quantified using live cell imaging with time-lapse microscopy [21] . EZH2 downregulation by shRNA or DZNeP in MDA-MB-231 cells significantly decreased the average cell velocity when compared to controls (Fig. 2a, b) . Furthermore, rescue of EZH2 expression using a myc-tagged EZH2 adenovirus partially reversed the decreased motility induced by EZH2 knockdown in MDA-MB-231 cells (Fig. 2c) . Collectively, these experiments show that EZH2 downregulation promotes a MET and reduces the motility and invasiveness of breast cancer cells.
EZH2 regulates the levels of phosphorylated p38 protein and signaling pathway
The p38 MAPK has emerged as an important regulator of cell migration and metastasis in breast cancer models [20, 21, 27] . Whether EZH2 influences the levels and function of p38 in human breast cancer is unknown. We found that EZH2 downregulation with shRNA or DZNeP reduced p-p38 protein and the phosphorylation of downstream targets MAPKAPK-2 (MK2) and heat shock protein 27 (HSP27) in breast cancer cell lines when compared to controls (Fig. 3a, Supplementary Fig. 2a) . No significant effect on the levels of total p38 was observed by EZH2 knockdown. Conversely, adenoviral overexpression of myc-tagged EZH2 in non-tumorigenic MCF10A breast cells and in MCF7 breast cancer cells consistently led to upregulation of p-p38 protein levels when compared to controls ( Supplementary Fig. 2b ).
To further define the mechanistic link between EZH2 and p38, we tested whether p-p38 regulates the levels of EZH2 and other core components of PRC2. Treatment with SB203580 or SB202190, which inhibit the ability of activated p-p38 to phosphorylate downstream targets, such as HSP27, had no effect on EZH2, SUZ12, EED, or H3K27me3 protein levels in MDA-MB-231 cells. These data indicate that EZH2 levels in breast cancer cells are not affected by p38 pathway activity (Fig. 3b) .
We next investigated whether EZH2 regulates a specific p38 isoform by testing the effect of EZH2 knockdown on the expression of phosphorylated p38a, p38b, p38c, and p38d. As phospho-specific isoform antibodies are not available, total p-p38 was immunoprecipitated from whole cell extracts of MDA-MB-231 and SUM149 cells expressing scrambled or EZH2-targeted shRNA followed by Western blot analysis for the four isoforms. EZH2 knockdown decreased the phosphorylated levels of all isoforms when compared to controls, while total p38 isoform protein levels remained unaffected (Fig. 3c, Supplementary  Fig. 3a ). Further supporting a non-transcriptional role for EZH2 in the regulation of p-p38, quantitative real-time RT-PCR showed that neither knockdown nor overexpression of EZH2 affected the mRNA levels of the p38 isoforms when c Activated, phosphorylated levels of all four p38 isoforms, but not total isoform protein levels, are decreased in SUM149 shEZH2 cells when compared to scrambled shRNA control cells. Total p-p38 was immunoprecipitated from whole cell extracts followed by Western blot analysis for the four individual isoforms. d Co-immunoprecipitations from whole cell extracts of SUM149 shEZH2 and scrambled shRNA control cells show that endogenous EZH2 immunoprecipitates with endogenous p-p38. Extracts were immunoprecipitated with EZH2, p-p38 or control IgG and bound proteins were revealed by Western blot via antibodies against EZH2 and p-p38. e Co-immunoprecipitations from whole cell extracts of SUM149 cells show that EZH2 binds p38/p-p38 in association with PRC2 members SUZ12 and EED. Extracts were immunoprecipitated with EZH2, p38, p-p38, EED, SUZ12 or control IgG and bound proteins were revealed by Western blot via antibodies against EZH2, p38, p-p38, EED, and SUZ12 compared to controls (Supplementary Fig. 3b) . Collectively, these results show that EZH2 regulates the phosphorylated levels of all p38 isoforms in breast cancer cells and suggest either an indirect transcriptional or a posttranscriptional regulatory mechanism.
EZH2 protein binds with phosphorylated p38 protein
To further understand the mechanism by which EZH2 regulates p-p38, we tested the hypothesis that EZH2 may bind to p-p38 in breast cancer cells. IP and Western blot analyses revealed that endogenous EZH2 protein interacts with p-p38 in SUM149 and MDA-MB-231 breast cancer cells; and that the binding is reduced by EZH2 knockdown, thereby supporting the specificity of the interaction (Fig. 3d, e) . Furthermore, reciprocal IP experiments demonstrated that EZH2 protein binds to p38/p-p38 protein in association with EED and SUZ12 (Fig. 3e) . As PRC2 functions in protein methylation, we hypothesized that PRC2 may methylate p38. Even though all p-p38 isoforms were affected by EZH2 protein expression, we chose to analyze p38a because it is the most abundant and ubiquitously expressed [28] . An in vitro methylation assay shows that addition of PRC2 leads to p38a protein methylation ( Supplementary Fig. 3c ). Collectively, these data demonstrate that EZH2 binds to p-p38 in association with PRC2, and show that PRC2 can methylate p38a in vitro, which paves the way for future mechanistic investigations.
EZH2 knockdown is sufficient to reduce distant metastasis
We have demonstrated that EZH2 knockdown decreases primary breast cancer tumor growth, but whether EZH2 downregulation impacts distant metastasis in breast cancer is unknown [17] . Compared to the scrambled shRNA control, EZH2 knockdown reduced the ability of MDA-MB-231 cells to form spontaneous lung metastasis when injected into the mammary fat pads of NOD/SCID mice (Fig. 4a, b) . Histologic analysis of lung tissues collected when primary tumors reached 2 cm 3 , revealed that 8 of 10 (80 %) MDA-MB-231/control mice developed metastases compared with 6 of 10 (60 %) of MDA-MB-231/shEZH2 mice. Although no significant difference was observed in the number of mice developing lung metastases between conditions, the metastatic burden as determined by the number of lung metastases per mouse was significantly reduced in shEZH2 mice in comparison to control mice (Fig. 4b) . In addition, the metastases formed by shEZH2 cells were smaller than controls; the average sizes of the largest lung metastasis per mouse were 304 and 737 lm from shEZH2 and control mice, respectively. Consistent with our functional findings, pathological analyses revealed a change in the invasive pattern of breast cancer cells at the metastatic site. The metastases formed by control cells exhibited irregular and infiltrative borders, and encased pre-existing normal structures such as bronchioles and blood vessels (Fig. 4a) . In contrast, metastases formed by shEZH2 cells were smaller and circumscribed, with round borders and minimal parenchymal infiltration (Fig. 4a) . Consistent with the in vitro data and the histopathologic findings, metastases formed by shEZH2 cells exhibited increased Cytokeratin-18 and decreased Snail1 proteins compared to metastases formed by the controls, as demonstrated by double immunohistochemical analyses (Fig. 4a) ; this effect was also observed in the primary xenografts ( Supplementary Fig. 4a ). EZH2 knockdown also significantly reduced cell proliferation in the metastases compared to controls (Supplementary Fig. 4b ). Supporting our in vitro observations and mechanistic studies, shEZH2 lung metastases had decreased p-p38 levels when compared to controls (Fig. 4c) .
Human breast cancer metastasis exhibit high EZH2 and p-p38 protein expression
The relevance of these novel findings to human breast cancer was validated by examining the expression of EZH2 and p-p38 proteins in a unique cohort of primary invasive carcinomas and their matched metastases from 16 patients, arrayed in tissue microarrays [25, 26] . When present, both proteins predominantly localized to the nuclei of breast cancer cells (Fig. 5a, b) . EZH2 and p-p38 were scored as exhibiting low or high expression according to a previously validated schema [14, 27] . We found that EZH2 was significantly upregulated in all metastases when compared to primary carcinomas, and that EZH2 and p-p38 were coexpressed in 63 % of the metastases (Fig. 5c) . The complete clinical and pathological information on these tumors is shown in Supplementary Table 1 .
Discussion
The data presented here reveal the previously undescribed findings that downregulation of EZH2 leads to MET, decreases motility, and is sufficient to reduce distant metastasis of breast cancer cells in vivo. We uncovered a novel mechanism of EZH2 function by which EZH2 protein binds to p-p38 and leads to upregulated expression of p-p38 protein and its signaling pathway in breast cancer cells.
It has become increasingly evident that cancer cell plasticity influences the biologic behavior of breast cancer by allowing the conversion between epithelial and . Right, bar graph shows p-p38 protein expression ± SEM in shEZH2 and control lung metastases quantified using FRIDA software (Student's t test, *p = 0.01) mesenchymal states [29, 30] . EMT describes the reversible and dynamic process in which epithelial cells, characterized as organized and polarized, undergo a change into mesenchymal-like cells, with alterations in cell polarization and intercellular junctions. The process of epithelial cancer cells acquiring attributes of mesenchymal-like cells has been shown to promote a motile state and to induce the development of metastasis [29] . One of the hallmarks of EMT is the reduction of normal expression of the cell-cell junction protein E-cadherin [30] . We and other investigators have reported that EZH2 overexpression induces invasion in non-tumorigenic breast cells, and decreases the expression of E-cadherin [14, 23] . However, whether EZH2 can influence EMT and motility of breast cancer cells has not been previously considered. In this study, we show that EZH2 downregulation is sufficient to reprogram the phenotype of breast cancer cells from spindle towards epithelial. EZH2 knockdown led to upregulation of the epithelial proteins E-cadherin and Cytokeratin-18, downregulation of the mesenchymal protein Vimentin and the EMT transcription factor Snail1, and resulted in decreased motility of breast cancer cells. The p38 MAPK has been established as a regulator of transitions between epithelial and mesenchymal states as well as cancer cell migration [20, 21, 27] . Activated p-p38 regulates transcription factors responsible for E-cadherin repression including Snail1, Slug (Snail2), and Twist inducing a mesenchymal-like phenotype [31] [32] [33] [34] . During TGF-b-induced EMT, p38 activation increases breast cancer lung metastasis [35] . p38a activity is required for the invasive capability of breast, pancreatic, hepatocellular, and head and neck squamous carcinoma cell lines, in part through regulation of matrix metalloproteinases implicated in extracellular remodeling and degradation [27, [36] [37] [38] [39] [40] [41] [42] [43] [44] . Also, p38d has been proposed to regulate the invasion of squamous cell carcinoma, while p38c has been associated with Ras-induced invasion [37, 45] . Recently, down-regulation of p38c markedly decreased the cell motility of breast cancer cells in vitro [21] . Despite the important role of p38 in motility, invasion, and metastasis of human cancer, the mechanisms regulating its activation are still being defined. Through a combination of knockdown and overexpression strategies, we found that EZH2 is a novel regulator of p-p38 protein levels and signaling pathway in non-tumorigenic breast cells and breast cancer cell lines. The mechanisms implicated in the oncogenic role of EZH2 need further investigation. EZH2 has been considered largely a transcriptional repressor of tumor suppressor genes as part of PRC2, but recent evidence supports contextual, activating functions of EZH2 [7] [8] [9] [10] 46] . Here, we demonstrate that EZH2 regulates p-p38 via a non-transcriptional mechanism. EZH2 had no effect on the mRNA levels of p38 isoforms using quantitative RT-PCR. Unexpectedly, in breast cancer cells, we found that endogenous EZH2, EED, and SUZ12 proteins bind to p-p38 protein, and that downregulation of EZH2 abrogates the binding of EZH2 and p-p38. Our in vitro methylation assay results suggest that PRC2 may methylate p-p38, and paves the way for future studies. Our data lead to the novel hypothesis that EZH2 in association with other PRC2 members may influence p-p38 activity, which is under investigation in our laboratory.
Our group has previously reported that high EZH2 protein expression is associated with the development of metastasis in breast cancer and worse clinical outcome [14] . Data presented here show for the first time that EZH2 knockdown reduces the number of distant breast cancer metastases in vivo. EZH2 knockdown in highly aggressive MDA-MB-231 cells decreased the metastatic burden and reduced the invasiveness of breast cancer cells at the metastatic site, as well as the expression of p-p38. In paired human samples of primary and metastatic carcinomas, EZH2 was significantly overexpressed in the metastases. Furthermore, co-expression of EZH2 and p-p38 were detected in 63 % of the metastatic carcinomas.
In conclusion, our results demonstrate a previously unknown mechanism of EZH2 function in breast cancer metastasis. We have shown that EZH2 inhibition in breast cancer cell lines leads to a phenotypic change from mesenchymal to epithelial, with reduced motility, invasion, and metastasis. We uncover a previously unknown molecular mechanism by which EZH2 binds to p-p38 and regulates the activation of the p38 signaling pathway. From a clinical perspective, the role of EZH2 in p38 signaling is of particular interest as activation of this pathway can be detectable and targetable in tumors to reduce breast cancer metastasis.
